CAMBRIDGE, MA--(Marketwire - March 13, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will release its fourth quarter, year-end 2008 financial results before the opening of the Market and will hold a conference call on Monday, March 16, 2009 at 10:00 a.m. Eastern Time. During the call, senior management of Molecular Insight will review the Company's financial results and provide an update on its clinical development programs.

Conference Call Details

To access the live call on March 16, 2009 at 10:00 a.m. Eastern Time, dial 800-299-7098 (or 617-801-9715 for international participants) at least five minutes prior to the start of the call. The participant pass code is 24456187. For one week following the call, an audio replay can be accessed by dialing 888-286-8010 (or 617-801-6888 for international callers) and using the pass code 77669400.

A live audio webcast of the call will also be available in the "Investor Relations" section of the Company's website, www.molecularinsight.com. An archived audio webcast will be available on the Company's website after the event and will be archived.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The Company is focused on discovering, developing, and commercializing innovative molecular imaging radiopharmaceuticals and targeted molecular radiotherapeutics with initial applications in the areas of cardiology and oncology. Molecular Insight's lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company's imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight's lead molecular radiotherapeutic product candidates, Azedra and Onalta™, are being developed for detection and treatment of cancer. In addition, the Company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. For more information, visit www.molecularinsight.com.